A Phase 1 interventional study of Efgartigimod PH20 SC via PFS and Efgartigimod PH20 SC via AI in Healthy Volunteer and Healthy Adult Participants, sponsored by argenx. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by argenx · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study is to compare the amount of efgartigimod in the blood over time after it is injected via Prefilled syringe (PFS) and Autoinjector (AI).
The study will comprise 2 study periods of 3 weeks each. Each participant receives both efgartigimod PH20 SC AI and PFS treatments, in a different order.
Participants will be in the study for up to approximately 9 weeks.
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive Efgartigimod PH20 SC via AI in period 1 and Efgartigimod PH20 SC via PFS in period 2
Biological: Efgartigimod PH20 SC via PFS · Biological: Efgartigimod PH20 SC via AI
Participants randomized to receive Efgartigimod PH20 SC via PFS in period 1 and Efgartigimod PH20 SC via AI in period 2
Biological: Efgartigimod PH20 SC via PFS · Biological: Efgartigimod PH20 SC via AI
Subcutaneous injection of empasiprubart via Prefilled syringe (PFS)
Subcutaneous injection of empasiprubart via Autoinjector (AI)
Primary PK parameter: Cmax
Cmax = maximum observed concentration
Time frame: Up to 9 weeks
Primary PK parameter: AUC0-inf
AUC0-inf = area under the curve from time 0 to infinity
Time frame: Up to 9 weeks
Secondary PK parameter: AUC0-t
AUC0-t = area under the curve from time 0 to the last measurable time point
Time frame: Up to 9 weeks
Secondary PK parameter: AUC0-168h
AUC0-168h = area under the curve from time 0 to 168 hours
Time frame: Up to 9 weeks
Secondary PK parameter: CL/F
CL/F = apparent clearance from plasma after extravascular administration
Time frame: Up to 9 weeks
Secondary PK parameter: Vz/F
Vz/F = apparent volume of distribution at steady state after extravascular administration
Time frame: Up to 9 weeks
Secondary PK parameter: Tmax
Tmax = time to Cmax
Time frame: Up to 9 weeks
Secondary PK parameter: t½
t½ = half-life
Time frame: Up to 9 weeks
Incidence of AEs, SAEs, and AEs leading to efgartigimod discontinuation
AE = adverse event ; SAE = serious adverse event
Time frame: Up to 9 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2026 to primary completion in Sep 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.